Abstract 12880: Left Ventricular Mass Predicts Cardiac Reverse Remodeling in Patients With Type 2 Diabetes and Coronary Artery Disease Who Are Treated With Empagliflozin
Abstract
Introduction:
Left ventricular (LV) hypertrophy is associated with an elevated risk for cardiovascular disease and all-cause mortality. The cardiovascular benefits of sodium-glucose cotransporter protein-2 (SGLT2) inhibitors have been attributed, in part, to cardiac reverse remodeling. The EMPA-HEART CardioLink-6 study previously reported that SGLT2 inhibition with empagliflozin for 6 months was associated with a significant reduction in LV mass indexed to body surface area (LVMi). We sought to determine in the same cohort if baseline LVMi influences empagliflozin-associated cardiac reverse remodelling.
Methods:
A total of 97 patients with type 2 diabetes and coronary artery disease was randomized to empagliflozin (10 mg/d) or matching placebo for 6 months in the EMPA-HEART CardioLink-6 study. This cohort was stratified into those with baseline LVMi <60 g/m
2
and those with LVMI ≥60 g/m
2
. Between-group comparisons were conducted using a linear regression model adjusted for baseline differences in LVMi (ANCOVA) that included an interaction term between baseline LVMi sub-group and treatment.
Results:
The effect empagliflozin had on the change in LVMi over 6 months was significantly different between patients with a baseline LVMi <60 g/m
2
and those whose LVMi was ≥60 g/m
2
. The adjusted difference between those randomized to empagliflozin and those assigned placebo after multivariable adjustment for baseline characteristics was 0.59 g/m
2
(95% CI: -3.01 g/m
2
, 4.19 g/m
2
,…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 97 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.